Epidermal Growth Factor Receptor – Page 2

FDA Approves Rybrevant for Third NSCLC Indication This Year

1 year ago talkbio0Tagged Approved, Epidermal Growth Factor Receptor, J&J, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, United States Food and Drug Administration

Rybrevant, NSCLC, FDA approval, J&J, EGFR mutations, lung cancer treatment

J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

1 year ago talkbio0Tagged Approved, chemotherapy-free regimen, Epidermal Growth Factor Receptor, Johnson & Johnson, lazertinib, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, United States Food and Drug Administration

Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen

AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront

1 year ago talkbio0Tagged AstraZeneca, Cancer Therapeutic Procedure, Epidermal Growth Factor Receptor, licensing agreement, milestone payments, molecular glues, Neoplasms, Pinetree, Protein Degradation, Metabolic, protein degrader, royalties

AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment

RYBREVANT: A Breakthrough in Lung Cancer Treatment

1 year ago talkbio0Tagged Epidermal Growth Factor Receptor, Infusion-Related Reaction, intravenous administration, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous administration, Survival Rate

RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)